Parenchyma-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma

Miyazaki, Masaru; Ito, Hiroshi; Nakagawa, Koji; Ambiru, Satoshi; Shimizu, Hiroaki; Okaya, Tomohisa; Shinmura, Kensuke; Nakajima, Nobuyuki

doi:10.1016/s1072-7515(99)00219-7

Cited by 112 publications

(113 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Extended lymphadenectomy is not recommended as there is no evidence showing survival advantage [168,172] . Radical resection of HCC has 5%-10% perioperative mortality rate, especially when extended hepatectomy (5 or more segments) is required [174,[206][207][208] . This partly relates to the increased rate of postoperative liver failure with major hepatic resections.…”

Section: Hccmentioning

confidence: 99%

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009

Aljiffry¹,

Walsh²,

Molinari³

2009

WJG

253

190

View full text Add to dashboard Cite

Several advances in diagnosis, treatment and palliation of cholangiocarcinoma (CC) have occurred in the last decades. A multidisciplinary approach to this disease is therefore recommended. CC is a relatively rare tumor and the main risk factors are: chronic inflammation, genetic predisposition and congenital abnormalities of the biliary tree. While the incidence of intra-hepatic CC is increasing, the incidence of extra-hepatic CC is trending down. The only curative treatment for CC is surgical resection with negative margins. Liver transplantation has been proposed only for selected patients with hilar CC that cannot be resected who have no metastatic disease after a period of neoadjuvant chemo-radiation therapy. Magnetic resonance imaging/ magnetic resonance cholangiopancreatography, positron emission tomography scan, endoscopic ultrasound and computed tomography scans are the most frequently used modalities for diagnosis and tumor staging. Adjuvant therapy, palliative chemotherapy and radiotherapy have been relatively ineffective for inoperable CC. For most of these patients biliary stenting provides effective palliation. Photodynamic therapy is an emerging palliative treatment that seems to provide pain relief, improve biliary patency and increase survival. The clinical utility of other emerging therapies such as transarterial chemoembolization, hepatic arterial chemoinfusion and high intensity intraductal ultrasound needs further study.

show abstract

Section: Hccmentioning

confidence: 99%

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009

Aljiffry¹,

Walsh²,

Molinari³

2009

WJG

253

190

View full text Add to dashboard Cite

show abstract

“…Major hepatectomy with pancreatoduodenectomy (hepatopancre atoduodenectomy) has been performed in selected patients with widespread disease. Miyazaki et al [49,50] reported that parenchyma-preserving hepatectomy could result in curative resection and improve the outcomes of patients with hilar cholangiocarcinoma localized to the hepatic duct confluence who do not require vascular resection. Lessextensive procedures were also beneficial for less-advanced disease if the resection margins were free of tumor.…”

Section: Operationmentioning

confidence: 99%

Diagnosis and initial management of cholangiocarcinoma with obstructive jaundice

Tajiri¹,

Yoshida²,

Mamada³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…[20][21][22][23] Recent advances in surgical resection of hilar cholangiocarcinoma allow access for potentially curative resections of high lesions. [24][25][26] These resections can be combined with a left or right hemihepatectomy, 27 which allows access to the hilum and anastomoses of a roux loop to second, or third order bile ducts can be safely performed.…”

Section: Discussionmentioning

confidence: 99%

Resource and manpower calculations for the provision of hepatobiliary surgical services in the UK

Majeed¹,

Price²

2004

Ann R Coll Surg Engl

View full text Add to dashboard Cite

G astrointestinal surgery in the UK is increasingly becoming sub-specialised into upper and lower gastrointestinal surgery with the management of patients being based on a multidisciplinary team approach. Upper gastrointestinal surgery is further divided into hepatopancreato-biliary surgery (HPB) and oesophago-gastric surgery.1 Most upper gastrointestinal surgeons treat patients with benign conditions affecting all these organs, but malignant conditions of the liver, bile duct and pancreas are increasingly dealt with by HPB surgeons 'super-specialising' in these organ systems. It is expected that a multidisciplinary approach to the management of upper GI cancer will allow better quality of care and decision-making and there is some evidence that Resource and manpower calculations for the provision of hepatobiliary surgical services in the UK

show abstract

Parenchyma-preserving hepatectomy in the surgical treatment of hilar cholangiocarcinoma

Cited by 112 publications

References 13 publications

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009

Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009

Diagnosis and initial management of cholangiocarcinoma with obstructive jaundice

Resource and manpower calculations for the provision of hepatobiliary surgical services in the UK

Contact Info

Product

Resources

About